

## HSV-2 Can Cause Recurrent Painful Outbreaks; The CBCD Reviews the Medical Evidence

Recurrent episodes of infection erupt when viral replication is stimulated. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, September 24, 2015 /EINPresswire.com/ --

"Infected with the herpes simplex virus (HSV-1 or HSV-2)? The CBCD recommends taking <u>Gene-Eden-VIR</u> or <u>Novirin</u> against the latent virus." – Greg Bennett, CBCD

When an individual is infected with a herpes virus (HSV-1 or HSV-2) in the genital region, it causes genital herpes. While HSV-1 can cause a nasty first outbreak, recurrent outbreaks are rare. This is not the case with HSV-2. Those infected with HSV-2 usually experience one or more painful outbreaks after the first outbreak. As Medscape notes, "recurrent episodes of infection erupt when viral replication is stimulated and virus returns via axons (nerve fibers) to the genital region to cause a clinical or subclinical recurrence (outbreak)." (1)

The Center for the Biology of Chronic Disease (CBCD) recommends that anyone who experiences recurrent genital herpes outbreaks take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was shown to reduce HSV symptoms in two separate post-marketing clinical studies that followed FDA guidelines. Additionally, it was designed to help the

immune system target the latent form of the virus.

Click to learn more about herpes symptoms.





The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Gene-Eden-VIR and Novirin formula HSV-1 and HSV-2. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with (HSV-1 or HSV-2)...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (2) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (2)

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites, here:

http://www.gene-eden-vir.com

and

## http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinensis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin shares the same formula as Gene-Eden-VIR. The difference between the two is that Novirin has higher quality and more expensive ingredients.

Recurrent genital herpes disease (recurring outbreaks) can be triggered by a number of different things. Medscape also notes that "several factors may trigger recurrences, including: Local trauma-friction from clothing, sexual intercourse, menstruation, stress, anxiety, depression, fatigue, ultraviolet light, intercurrent infections, Recurrent genital herpes affects people with different degrees of severity. Some recurrences are mild and virtually asymptomatic, while others manifest as debilitating disease with severe prodromal symptoms and lesions affecting a significant genital area. Approximately 80% of persons having an HSV-2 first episode will have at least 1 recurrence, while 50% of persons with HSV-1 will have a recurrence." (1)

What treatments are available for herpes infections?

"Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day." (2) There are also the natural supplements Novirin and Gene-Eden-VIR, which have a formula that was designed to help the immune system target the herpes virus when it is in a latent form.

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure. However, two clinical studies, published in peer reviewed medical journals showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was shown to safely and effectively reduce herpes symptoms. Additionally, it was designed to help the immune system target the latent virus.

"We recommend that individuals who are infected with a latent herpes virus, take Gene-Eden-VIR or

Find us on Facebook here: <u>https://www.facebook.com/GeneEdenVIR</u> Follow us Twitter here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Medscape.com - Genital Herpes: Recognizing the Problem."Recurrent Episodes of HSV Infection" Medscape General Medicine. 1997;1(2)

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

Greg Bennett CBCD 585-250-9999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.